Jun Guo

9.5k citations

208 papers · 3.5k · 1 hit paper · h-index 30

Impact in

Oncology top 1%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 5%
- Immunotherapy and Immune Responses

Papers in

Oncology 138
- Cutaneous Melanoma Detection and Management 63
- Cancer Immunotherapy and Biomarkers 57
- CAR-T cell therapy research 50
Molecular Biology 96
- Melanoma and MAPK Pathways 56
- Renal and related cancers 19

Co-authors: Lu Si (133 shared papers)Xinan Sheng (107 shared papers)Chuanliang Cui (100 shared papers)Zhihong Chi (101 shared papers)Lili Mao (59 shared papers)Yan Kong (67 shared papers)Bin Lian (78 shared papers)Jie Dai (55 shared papers)
Journals: Journal of Clinical Oncology (69 papers)Annals of Oncology (14 papers)Clinical Cancer Research (7 papers)BMC Cancer (6 papers)European Journal of Cancer (6 papers)
Partner nations: China United States Ethiopia

In The Last Decade

Jun Guo

193 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma 2020 · 192 citations

Peers

Countries citing papers authored by Jun Guo

Since Specialization

Citations

This map shows the geographic impact of Jun Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Guo more than expected).

Fields of papers citing papers by Jun Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Guo. The network helps show where Jun Guo may publish in the future.

Co-authors

The 25 scholars most cited alongside Jun Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jun Guo Line = papers co-authored together Jun Guo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 208 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases BMC Cancer ·Zhihong Chi, Siming Li, Xinan Sheng, Lu Si, Chuanliang Cui, Mei Han, Jun Guo	2011	269
2	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Clinical Cancer Research ·Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Chang-Lu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, Jun Guo Hit paper breakdown →	2020	192
3	Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma Clinical Cancer Research ·Yan Kong, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lü, Jun Guo	2011	181
4	Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients Journal of Hematology & Oncology ·Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo	2018	140
5	Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Clinical Cancer Research ·Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, Jun Guo	2013	121
6	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions Frontiers in Immunology ·Lili Mao, Zhonghui Qi, Li Zhang, Jun Guo, Lu Si	2021	100
7	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151) Translational Oncology ·Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Yu Zhou, Jun Ge, Jianfeng Li, Haiyan Wu, Jun Guo	2019	99
8	The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients Annals of Oncology ·Bin Lian, C-L. Cui, Li Zhou, Xiao‐Tong Song, X.S. Zhang, Di Wu, Lu Si, Z. Chi, X. N. SHENG, Lanfang MAO, X. Wang, B.X. Tang, Xuena Yan, Yan Kong, Jie Dai, Sm Li, Xue Bai, Nan Zheng, Charles M. Balch, Jun Guo	2016	95
9	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma Molecular Therapy ·Chuanliang Cui, Lili Mao, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Siming Li, Bin Lian, Kangsheng Gu, Min Tao, Xin Song, Tongyu Lin, Xiubao Ren, Shukui Qin, Jun Guo	2013	83
10	Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery Life Sciences ·Kai Sun, Chuan‐She Wang, Jun Guo, Yoshinori Horie, Su-Ping Fang, Fang Wang, Yuying Liu, Lian-Yi Liu, Jiying Yang, Jing‐Yu Fan, Jing‐Yan Han	2007	79
11	MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases Clinical Cancer Research ·Xue Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian, Xieqiao Yan, Li Zhou, Jie Dai, Jun Guo, Lu Si	2017	72
12	Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma npj Genomic Medicine ·Chuanliang Cui, Canqiang Xu, Wenxian Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Jinyu Yu, Shun Wang, Rongshan Yu, Jun Guo, Yan Kong	2021	61
13	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors Clinical Cancer Research ·Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo	2015	58
14	Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial Annals of Oncology ·Robert J. Motzer, Thomas E. Hutson, James A. Reeves, Robert D. Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan, Kate Fife, Jie Jin, Robert J. Jones, Hirotsugu Uemura, Ugo De Giorgi, Ulrika Harmenberg, J. Wang, David Cella, Lauren McCann, Keith C. Deen, Toni K. Choueiri	2012	57
15	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis European Journal of Cancer ·Xinan Sheng, Yan Kong, Yiqian Li, Qiannan Zhang, Lu Si, Chuanliang Cui, Zhihong Chi, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, Jie Dai, Jun Guo	2016	49
16	Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients British Journal of Ophthalmology ·Xinan Sheng, Siming Li, Zhihong Chi, Lu Si, Chuanliang Cui, Lili Mao, Bin Lian, Bixia Tang, Xuan Wang, Xieqiao Yan, Yan Kong, Jie Dai, Jun Guo	2015	47
17	RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma Cell Death and Disease ·Sifan Yu, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Chuanliang Cui, Zhihong Chi, Lu Si, Huan Tang, Lu Yang, Xinan Sheng, Jun Guo	2019	43
18	miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy Journal of Experimental & Clinical Cancer Research ·Huan Tang, Meng Ma, Jie Dai, Chuanliang Cui, Lu Si, Xinan Sheng, Zhihong Chi, Longwen Xu, Sifan Yu, Tianxiao Xu, Junya Yan, Huan Yu, Lu Yang, Yan Kong, Jun Guo	2019	43
19	Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma BMC Cancer ·Siming Li, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Jun Guo	2014	39
20	Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib Clinical Cancer Research ·Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, Jun Guo	2013	38

About Jun Guo

Jun Guo is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 208 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (63 papers), Cancer Immunotherapy and Biomarkers (57 papers), Melanoma and MAPK Pathways (56 papers), CAR-T cell therapy research (50 papers), Renal cell carcinoma treatment (39 papers), Immunotherapy and Immune Responses (29 papers), Cancer Genomics and Diagnostics (22 papers) and Renal and related cancers (19 papers). The work is most often cited by research in Oncology (2.3k citations), Immunology (820 citations), Cancer Research (519 citations), Molecular Biology (1.7k citations) and Pulmonary and Respiratory Medicine (642 citations). Jun Guo has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Lu Si, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Bin Lian, Jie Dai, Bixia Tang and Xieqiao Yan. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, BMC Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Jun Guo

Impact in

Papers in i

In The Last Decade

Jun Guo

Hit Papers

Peers

Countries citing papers authored by Jun Guo

Fields of papers citing papers by Jun Guo

All Works

About Jun Guo

Explore authors with similar magnitude of impact

Papers in